Structural origins of AGC protein kinase inhibitor selectivities: PKA as a drug discovery tool

Biological Chemistry

Volumn 393, Issue 10, 2012, Pages 1121-1129

  Åberg, Espen ^a   Lund, Bjarte ^a   Pflug, Alexander ^a   Gani, Osman A B S M ^a   Rothweiler, Ulli ^a   De Oliveira, Taianà M ^a   Engh, Richard A ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

A nticancer; Crystallography; Drug design; Phosphotransferase; Surrogate

Indexed keywords

ADENOSINE TRIPHOSPHATE; AGC PROTEIN KINASE INHIBITOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYSTEINE; GLUTAMINE; GLYCINE; METHIONINE; PHENYLALANINE; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME CONFORMATION; ENZYME STRUCTURE; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOLECULAR STABILITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG DISCOVERY; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN KINASE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 84869409544     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2012-0248     Document Type: Review

References (36)

1. Anastassiadis, T., Deacon, S.W., Devarajan, K., Ma, H., and Peterson, J.R. (2011). Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039-1045.
2. Ashton, K.S., St Jean, D.J. Jr., Poon, S.F., Lee, M.R., Allen, J.G., Zhang, S., Lofgren, J.A., Zhang, X., Fotsch, C., and Hungate, R. (2011). Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2. Bioorg. Med. Chem. Lett. 21, 5191- 5196.
3. Bonn, S., Herrero, S., Breitenlechner, C.B., Erlbruch, A., Lehmann, W., Engh, R.A., Gassel, M., and Bossemeyer, D. (2006). Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity. J. Biol. Chem. 281, 24818-24830.
4. Bossemeyer, D., Engh, R.A., Kinzel, V., Ponstingl, H., and Huber, R. (1993). Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 Å structure of the complex with Mn 2 + adenylyl imidodiphosphate and inhibitor peptide PKI(5-24). EMBO J. 12, 849-859.
5. Breitenlechner, C., Gassel, M., Hidaka, H., Kinzel, V., Huber, R., Engh, R.A., and Bossemeyer, D. (2003). Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure 11, 1595-1607.
6. Breitenlechner, C.B., Friebe, W.-G., Brunet, E., Werner, G., Graul, K., Thomas, U., Kuenkele, K.-P., Schaefer, W., Gassel, M., Bossemeyer, D., et al. (2005). Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. J. Med. Chem. 48, 163-170.
7. Copeland, R.A. (2011). Conformational adaptation in drug-target interactions and residence time. Future Med. Chem. 3, 1491-1501.
8. Davies, T.G., Woodhead, S.J., and Collins, I. (2009). Fragment-based discovery of inhibitors of protein kinase B. Curr. Top. Med. Chem. 9, 1705-1717.
9. Davis, M.I., Hunt, J.P., Herrgard, S., Ciceri, P., Wodicka, L.M., Pallares, G., Hocker, M., Treiber, D.K., and Zarrinkar, P.P. (2011). Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051.
10. Engh, R.A., Girod, A., Kinzel, V., Huber, R., and Bossemeyer, D. (1996). Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity. J. Biol. Chem. 271, 26157-26164.
11. Enkvist, E., Lavogina, D., Raidaru, G., Vaasa, A., Viil, I., Lust, M., Viht, K., and Uri, A. (2006). Conjugation of adenosine and hexa- (d -arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases. J. Med. Chem. 49, 7150-7159.
12. Fabbro, D., Cowan-Jacob, S.W., Möbitz, H., and Martiny-Baron, G. (2012). Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol. Biol. 795, 1-34.
13. Gassel, M., Breitenlechner, C.B., Rueger, P., Jucknischke, U., Schneider, T., Huber, R., Bossemeyer, D., and Engh, R.A. (2003). Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT). J. Mol. Biol. 329, 1021-1034.
14. Gassel, M., Breitenlechner, C.B., König, N., Huber, R., Engh, R.A., and Bossemeyer, D. (2004). The protein kinase C inhibitor bisindolyl maleimide 2 binds with reversed orientations to different conformations of protein kinase A. J. Biol. Chem. 279, 23679-23690.
15. Hines, A.C. and Cole, P.A. (2004). Design, synthesis, and characterization of an ATP-peptide conjugate inhibitor of protein kinase A. Bioorg. Med. Chem. Lett. 14, 2951-2954.
16. Lamba, V. and Ghosh, I. (2012). New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors. Curr. Pharm. Des. 18, 2936-2945.
17. Leproult, E., Barluenga, S., Moras, D., Wurtz, J.M., and Winssinger, N. (2011). Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J. Med. Chem. 54, 1347-1355.
18. Liu, Y., Bishop, A., Witucki, L., Kraybill, B., Shimizu, E., Tsien, J., Ubersax, J., Blethrow, J., Morgan, D.O., and Shokat, K.M. (1999). Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol. 6, 671-678.
19. Lopez-Garcia, L.A., Schulze, J.O., Fröhner, W., Zhang, H., Süss, E., Weber, N., Navratil, J., Amon, S., Hindie, V., Zeuzem, S., et al. (2011). Allosteric regulation of protein kinase PKC ξby the N-terminal C1 domain and small compounds to the PIF-pocket. Chem. Biol. 18, 1463-1473.
20. Masterson, L.R., Shi, L., Metcalfe, E., Gao, J., Taylor, S.S., and Veglia, G. (2011). Dynamically committed, uncommitted, and quenched states encoded in protein kinase A revealed by NMR spectroscopy. Proc. Natl. Acad. Sci. USA 108, 6969-6974.
21. Miller, M.L., Jensen, L.J., Diella, F., Jørgensen, C., Tinti, M., Li, L., Hsiung, M., Parker, S.A., Bordeaux, J., Sicheritz-Ponten, T., et al. (2008). Linear motif atlas for phosphorylation-dependent signaling. Sci. Signal. 1, ra2.
22. Nagashima, K., Shumway, S.D., Sathyanarayanan, S., Chen, A.H., Dolinski, B., Xu, Y., Keilhack, H., Nguyen, T., Wiznerowicz, M., Li, L., et al. (2011). Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. J. Biol. Chem. 286, 6433-6448.
23. Narayana, N., Diller, T.C., Koide, K., Bunnage, M.E., Nicolaou, K.C., Brunton, L.L., Xuong, N.H., Ten Eyck, L.F., and Taylor, S.S. (1999). Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP-dependent protein kinase. Biochemistry 38, 2367-2376.
24. Oliveira, T.M., Ahmad, R., and Engh, R.A. (2011). VX680 binding in Aurora A: π-π interactions involving the conserved aromatic amino acid of the flexible glycine-rich loop. J. Phys. Chem. A 115, 3895-3904.
25. Pflug, A., Rogozina, J., Lavogina, D., Enkvist, E., Uri, A., Engh, R.A., and Bossemeyer, D. (2010). Diversity of bisubstrate binding modes of adenosine analogue-oligoarginine conjugates in protein kinase A and implications for protein substrate interactions. J. Mol. Biol. 403, 66-77.
26. Pflug, A., de Oliveira, T.M., Bossemeyer, D., and Engh, R.A. (2011). Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase. Biochem. J. 440, 85-93.
27. Prade, L., Engh, R.A., Girod, A., Kinzel, V., Huber, R., and Bossemeyer, D. (1997). Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure 5, 1627-1637.
28. Rabiller, M., Getlik, M., Klüter, S., Richters, A., T ückmantel, S., Simard, J.R., and Rauh, D. (2010). Proteus in the world of proteins: conformational changes in protein kinases. Arch. Pharm. (Weinheim) 343, 193-206.
29. Schneider, T.L., Mathew, R.S., Rice, K.P., Tamaki, K., Wood, J.L., and Schepartz, A. (2005). Increasing the kinase specificity of k252a by protein surface recognition. Org. Lett. 7, 1695-1698.
30. Schwartz, P.A. and Murray, B.W. (2011). Protein kinase biochemistry and drug discovery. Bioorg. Chem. 39, 192-210.
31. Toral-Barza, L., Zhang, W.G., Huang, X., McDonald, L.A., Salaski, E.J., Barbieri, L.R., Ding, W.D., Krishnamurthy, G., Hu, Y.B., Lucas, J., et al. (2007). Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/ PKB: mechanistic involvement of AKT catalytic activation loop cysteines. Mol. Cancer Ther. 6, 3028- 3038.
32. Vasudevan, K.M., Barbie, D.A., Davies, M.A., Rabinovsky, R., McNear, C.J., Kim, J.J., Hennessy, B.T., Tseng, H., Pochanard, P., Kim, S.Y., et al. (2009). AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16, 21-32.
33. Zeng, L., Webster, S.V., and Newton, P.M. (2012). The biology of protein kinase C. Adv. Exp. Med. Biol. 740, 639-661.
34. Zhang, J., Yang, P.L., and Gray, N.S. (2009). Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39.
35. Zhang, V.M., Chavchich, M., and Waters, N.C. (2012). Targeting protein kinases in the malaria parasite: update of an antimalarial drug target. Curr. Top. Med. Chem. 12, 456-472.
36. Zheng, J., Knighton, D.R., Ten Eyck, L.F., Karlsson, R., Xuong, N.-H., Taylor, S.S., and Sowadski, J.M. (1993). Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry 32, 2154-2161.